Economic evaluation of second generation pneumococcal conjugate vaccines in Norway

► We model cost-effectiveness of the three conjugate pneumococcal vaccines in Norway. ► We estimate costs and epidemiological burden of pneumococcal and NTHi. ► PHiD-CV and PCV13 give similar protection against deaths, IPD, sequelae and pneumonia. ► PHiD-CV addresses AOM and myringotomy more effectively than PCV13. ► PHiD-CV saves more treatment and indirect costs and is more cost-effective.